Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma Company...
Completion of Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 27, 2024 – Genmab A/S (Nasdaq: GMAB) announces that...
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Company Announcement...
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 24, 2024 – Genmab A/S (Nasdaq: GMAB...
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; June 18, 2024 – Genmab A/S...
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 17, 2024 – Genmab A/S (Nasdaq: GMAB...
Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; June 12, 2024 – Genmab A/S...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company...
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 10, 2024 – Genmab A/S (Nasdaq: GMAB...
Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference Media Release COPENHAGEN, Denmark;...
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 3, 2024 – Genmab A/S (Nasdaq: GMAB). On...
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and...
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in...
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2...
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 27, 2024 – Genmab A/S (Nasdaq: GMAB). On...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.